IP Library Granted Patent US 9,834,577
Granted Patent B2
US 9,834,577 · App. 15/411,409 · Granted Dec 5, 2017

Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate

Inventors: Venkata Lakshmi Narasimha Rao Dammalapati (Hyderabad, IN); Mani Bushan Kotala (Hyderabad, IN); Shankar Madhavaram (Hyderabad, IN)
Assignee: Laurus Labs Limited
C07H19/10C07H1/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,834,577
App. No.
15/411,409
Granted
Dec 5, 2017
Kind
B2
Abstract

The present invention provides a process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate of Formula I in high yield and purity.

Claims (38)

1. A process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)]phosphate of Formula I,

the process comprising:

a) reacting protected gemcitabine derivative of Formula IV

wherein

P 1 is a hydroxy protecting group independently selected from the group consisting of optionally substituted —Si(C 1-6 alkyl) 3 , optionally substituted —C(O)—C 1 -C 6 -alkyl, optionally substituted —C(O)-aryl, optionally substituted —C(O)—OC 1 -C 6 -alkyl, —C(O)—O-allyl, —C(O)—O—CH 2 -fluorenyl, optionally substituted —CH(aryl) 3 , optionally substituted —(C 1 -C 3 -alkylene)-aryl, optionally substituted —C(O)OCH 2 -aryl, and —C 1 -C 4 -alkyl-O—C 1 -C 4 -alkyl;

P 2 represents an amine protecting group independently selected from the group consisting of —C(O)OC 1 -C 6 -alkyl, optionally substituted —C(O)OCH 2 -aryl, —C(O)—O-allyl, —C(O)—O—CH 2 -fluorenyl, optionally substituted —CH(aryl) 3 , optionally substituted —(C 1 -C 3 -alkylene)-aryl, optionally substituted —C(O)—C 1 -C 6 -alkyl, optionally substituted —C(O)-aryl, —S(O) 2 —C 1 -C 6 -alkyl, optionally substituted —S(O) 2 -aryl, and optionally substituted —Si(C 1-6 alkyl) 3 ; and

P 3 represents a hydrogen or an amine protecting group independently selected from the group consisting of —C(O)OC 1 -C 6 -alkyl, optionally substituted —C(O)OCH 2 -aryl, —C(O)—O-allyl, —C(O)—O—CH 2 -fluorenyl, optionally substituted —CH(aryl) 3 , optionally substituted —(C 1 -C 3 -alkylene)-aryl, optionally substituted —C(O)—C 1 -C 6 -alkyl, optionally substituted —C(O)-aryl, —S(O) 2 —C 1 -C 6 -alkyl, optionally substituted —S(O) 2 -aryl, and optionally substituted —Si(C 1-6 alkyl) 3 ;

with ProTide intermediate of Formula III, wherein “X” is a leaving group,

to obtain protected phosphoramidate of Formula II

b) deprotecting the protected phosphoramidate of Formula II to obtain gemcitabine-[phenyl(benzoxy-L-alaninyl)]phosphate by exposing the phosphoramidate of Formula II to a reagent selected from the group consisting of a Bronsted acid; a Lewis acid; a base; a fluorine source; H 2 and a catalyst an oxidizing agent (PPh 3 ) 4 Pd; and piperidine.

2. The process of claim 1 , wherein X is selected from the group consisting of Cl, Br, I, tosylate, mesylate, trifluoroacetate, triflurosulfonate.

3. The process of claim 1 , wherein step a) is conducted in the presence of a base.

4. The process of claim 3 , wherein the base is tBuMgCl.

5. A process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)]phosphate of Formula I,

comprising:

a) deprotecting a protected phosphoramidate of Formula II to obtain gemcitabine-[phenyl(benzoxy-L-alaninyl)]phosphate of Formula I by exposing the phosphoramidate of Formula II to a reagent selected from the group consisting of a Bronsted acid; a Lewis acid; a base; a fluorine source; H 2 and a catalyst an oxidizing agent (PPh 3 ) 4 Pd; and piperidine;

wherein

P 1 is a hydroxy protecting group independently selected from the group consisting of optionally substituted —Si(C 1-6 alkyl) 3 , optionally substituted —C(O)—C 1 -C 6 -alkyl, optionally substituted —C(O)-aryl, optionally substituted —C(O)—OC 1 -C 6 -alkyl, —C(O)—O-allyl, —C(O)—O—CH 2 -fluorenyl, optionally substituted —CH(aryl) 3 optionally substituted —(C 1 -C 3 -alkylene)-aryl, optionally substituted —C(O)OCH 2 -aryl, and —C 1 -C 4 -alkyl-O—C 1 -C 4 -alkyl;

P 2 represents an amine protecting group independently selected from the group consisting of —C(O)OC 1 -C 6 -alkyl, optionally substituted —C(O)OCH 2 -aryl, —C(O)—O-allyl, —C(O)—O—CH 2 -fluorenyl, optionally substituted —CH(aryl) 3 , optionally substituted —(C 1 -C 3 -alkylene)-aryl, optionally substituted —C(O)—C 1 -C 6 -alkyl, optionally substituted —C(O)-aryl, —S(O) 2 —C 1 -C 6 -alkyl, optionally substituted —S(O) 2 -aryl, and optionally substituted —Si(C 1-6 alkyl) 3 ; and

P 3 represents a hydrogen or an amine protecting group independently selected from the group consisting of —C(O)OC 1 -C 6 -alkyl, optionally substituted —C(O)OCH 2 -aryl, —C(O)—O-allyl, —C(O)—O—CH 2 -fluorenyl, optionally substituted —CH(aryl) 3 optionally substituted —(C 1 -C 3 -alkylene)-aryl, optionally substituted —C(O)—C 1 -C 6 -alkyl, optionally substituted —C(O)-aryl, —S(O) 2 —C 1 -C 6 -alkyl, optionally substituted —S(O) 2 -aryl, and optionally substituted —Si(C 1-6 alkyl) 3 .

6. The process of claim 5 , wherein P 1 is independently selected from the group consisting of optionally substituted —Si(C 1-6 alkyl) 3 , optionally substituted —C(O)—OC 1 -C 6 -alkyl, optionally substituted —C(O)OCH 2 -aryl, and —C(O)—O-allyl.

7. The process of claim 5 , wherein P 1 is C(O)—O-tBu.

8. The process of claim 5 , wherein P 2 is independently selected from the group consisting of —C(O)OC 1 -C 6 -alkyl, optionally substituted —C(O)OCH 2 -aryl, —C(O)—O-allyl, optionally substituted —CH(aryl) 3 , and optionally substituted —Si(C 1-6 alkyl) 3 .

9. The process of claim 5 , wherein P 2 is C(O)—O-tBu.

10. The process of claim 5 , wherein P 3 is H.

11. The process of claim 7 , wherein the deprotection step is conducted using a Bronsted acid.

12. The process of claim 11 , wherein the Bronsted acid is TFA.

13. A compound of formula II

wherein

P 1 is a hydroxy protecting group independently selected from the group consisting of optionally substituted —Si(C 1-6 alkyl) 3 , optionally substituted —C(O)—C 1 -C 6 -alkyl, optionally substituted —C(O)-aryl, optionally substituted —C(O)—OC 1 -C 6 -alkyl, —C(O)—O-allyl, —C(O)—O—CH 2 -fluorenyl, optionally substituted —CH(aryl) 3 , optionally substituted —(C 1 -C 3 -alkylene)-aryl, optionally substituted —C(O)OCH 2 -aryl, and —C 1 -C 4 -alkyl-O—C 1 -C 4 -alkyl;

P 2 represents an amine protecting group independently selected from the group consisting of —C(O)OC 1 -C6-alkyl, optionally substituted —C(O)OCH 2 -aryl, —C(O)—O-allyl, —C(O)—O—CH 2 -fluorenyl, optionally substituted —CH(aryl) 3 , optionally substituted —(C 1 -C 3 -alkylene)-aryl, optionally substituted —C(O)—C 1 -C 6 -alkyl, optionally substituted —C(O)-aryl, —S(O) 2 —C 1 -C 6 -alkyl, optionally substituted —S(O) 2 -aryl, and optionally substituted —Si(C 1-6 alkyl) 3 ; and

P 3 represents a hydrogen or an amine protecting group independently selected from the group consisting of —C(O)OC 1 -C 6 -alkyl, optionally substituted —C(O)OCH 2 -aryl, —C(O)—O-allyl, —C(O)—O—CH 2 -fluorenyl, optionally substituted —CH(aryl) 3 optionally substituted —(C 1 -C 3 -alkylene)-aryl, optionally substituted —C(O)—C 1 -C 6 -alkyl, optionally substituted —C(O)-aryl, —S(O) 2 —C 1 -C 6 -alkyl, optionally substituted —S(O) 2 -aryl, and optionally substituted —Si(C 1-6 alkyl) 3 .

14. The process of claim 9 , wherein the deprotection step is conducted using a Bronsted acid.

15. The process of claim 14 , wherein the Bronsted acid is TFA.

16. The process of claim 1 , wherein P 1 is C(O)—O-tBu.

17. The process of claim 16 , wherein the deprotection step is conducted using a Bronsted acid.

18. The process of claim 1 , wherein P 2 is C(O)—O-tBu.

19. The process of claim 18 , wherein the deprotection step is conducted using a Bronsted acid.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2020
From: LAURUS LABS LIMITED
To: NUCANA PLC
Reel/Frame 054079/0141 →
CHANGE OF NAME Recorded Oct 16, 2020
From: NUCANA BIOMED LIMITED
To: NUCANA PLC
Reel/Frame 054079/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2017
From: MADHAVARAM, SHANKAR; DAMMALAPATI, VENKATA LAKSHMI NARASIMHA RAO; KOTALA, MANI BUSHAN
To: LAURUS LABS PRIVATE LTD.
Reel/Frame 041749/0759 →
CHANGE OF NAME Recorded Mar 27, 2017
From: LAURUS LABS PRIVATE LTD.
To: LAURUS LABS LIMITED
Reel/Frame 042097/0870 →
Priority Claims (2)
IN 3585/CHE/2014 · Jul 22, 2014 · national
GB 1414880.3 · Aug 21, 2014 · national
Continuity (1)
Related Publication 20170166602A1 · Jun 15, 2017